Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022104 | 1.00 | HTR2A (0.47) | HTR2AKCNH2HTR2CCYP2D6COMT | |
| SCHEMBL4016124 | 0.89 | HTR2A (0.57) | HTR2AKCNH2HTR2CCOMTPTGS1 | |
| SCHEMBL4016125 | 0.89 | HTR2A (0.57) | HTR2AKCNH2HTR2CCOMTPTGS1 | |
| SCHEMBL4014219 | 0.88 | NFE2L2 (0.51) | HTR2AKCNH2HTR2CNFE2L2 | |
| SCHEMBL4014216 | 0.88 | NFE2L2 (0.51) | HTR2AKCNH2HTR2CNFE2L2 | |
| SCHEMBL4013305 | 0.81 | HTR2A (0.50) | HTR2AKCNH2HTR2CCYP2D6COMT | |
| SCHEMBL4013310 | 0.81 | HTR2A (0.50) | HTR2AKCNH2HTR2CCYP2D6COMT | |
| SCHEMBL3157531 | 0.81 | HTR2A (0.62) | HTR2AKCNH2HTR2CCYP2D6PTGS1 | |
| SCHEMBL3157527 | 0.81 | HTR2A (0.62) | HTR2AKCNH2HTR2CCYP2D6PTGS1 | |
| SCHEMBL4012497 | 0.79 | HTR2A (0.48) | HTR2AKCNH2HTR2CCYP2D6COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | claimed |
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | HTR2A 1/4885KCNH2 1308/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.